Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies

Karthivashan, Govindarajan; Ganesan, Palanivel; Park, Shin-Young; Lee, Ho‐Won; Choi, Dong‐Kug

doi:10.1016/j.biomaterials.2019.119704

Cited by 27 publications

(22 citation statements)

References 287 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although dopamine neurons are very few in number compared to the total neuronal population in the brain (< 1/100,000), they are involved in neuroendocrine regulation, mood, motivation, and psychological processes, including working memory and learning [111,112]. Although no specific mechanism has yet been confirmed, the inhibition of tyrosine hydroxylase activity and tyrosine conversion into dopamine and norepinephrine are involved in long-term memory formation [116]. For example, vasopressin is a hypothalamic neuropeptide found to improve memory and does so by interacting with dopamine in the amygdala and serotonin of the hippocampus [117].…”

Section: Dopamine Receptorsmentioning

confidence: 99%

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

Azam

Haque

Jakaria

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

Neurodegenerative diseases are a large group of neurological disorders with diverse etiological and pathological phenomena. However, current therapeutics rely mostly on symptomatic relief while failing to target the underlying disease pathobiology. G-protein-coupled receptors (GPCRs) are one of the most frequently targeted receptors for developing novel therapeutics for central nervous system (CNS) disorders. Many currently available antipsychotic therapeutics also act as either antagonists or agonists of different GPCRs. Therefore, GPCR-based drug development is spreading widely to regulate neurodegeneration and associated cognitive deficits through the modulation of canonical and noncanonical signals. Here, GPCRs’ role in the pathophysiology of different neurodegenerative disease progressions and cognitive deficits has been highlighted, and an emphasis has been placed on the current pharmacological developments with GPCRs to provide an insight into a potential therapeutic target in the treatment of neurodegeneration.

show abstract

Section: Dopamine Receptorsmentioning

confidence: 99%

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

Azam

Haque

Jakaria

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…Orain arte, PGren aurkako tratamendu berrien erronkarik handiena hesi hematoentzefalikoa (HHE) zeharkatzeko estrategiak garatzea izan da. HHE garuneko hesi fisiologikoa da, eta garunaren eta odolhodien arteko substantzien trukaketa kontrolatzen du, molekula gehienak garunera iristea eragotziz [8][9][10]. HHEk iragazkortasun txikia eta selektiboa du, ia molekula handi guztiak eta molekula txikien %98 garunean sartzea oztopatuz [8,11].…”

Section: Sarreraunclassified

“…Aldiz, substantzia lipofilikoak erraz sar daitezke garuneko parenkiman transzitosiaren bidez [8,10].…”

Section: Sarreraunclassified

See 1 more Smart Citation

Estrategia terapeutiko berritzaileak Parkinson gaixotasunean: nanopartikulak

Zubelzu,

Razquin,

Vaquero-Rodriguez

et al. 2023

EKAIA

View full text Add to dashboard Cite

Parkinson gaixotasuna (PG) nahasmendu neurodegeneratibo motor ohikoena da, substantia nigra pars compacta-ko (SNc) neurona dopaminergikoen galeragatik eta horrek eragindako mugitzeko desgaitasunagatik bereizten dena. Klinikan gehien erabiltzen diren egungo tratamenduek, hala nola lebodopak, garuneko neurotransmisio dopaminergikoa lehengoratzen dute. Hala ere, tratamendu horiek sintomatikoak baino ez dira, denbora pasa ahala eraginkortasuna galtzen dute eta eragin kaltegarri larriak eragiten dituzte. Eragin kaltegarrietako batzuk administrazio bidearekin lotuta daude; izan ere, aho-bidezko farmakoek hartzaile dopaminergikoen aktibazio ez-jarraitua eragiten dute, tratamenduarekin lotutako asaldura motorren agerpena bultzatuz. Horregatik, tratamendu berritzaileak aurkitzeaz gain, segurtasun-profil hobeak dituzten administrazio-sistema berriak garatzea beharrezkoa da. Hala, azken urteetan nanopartikulen eraginkortasuna aztertzen duten ikerketa desberdinak burutu dira. Izan ere, nanopartikulek hesi hematoentzefalikoa (HHE) erraz zeharkatzeaz gain, farmakoen bioerabilgarritasuna eta eraginkortasuna hobetuz eragin kaltegarriak minimizatzen dituzte. Nanogarraiatzaile organiko eta ez-organiko desberdinak erabiliz, lebodopa, agonista dopaminergikoak edo faktore neurotrofikoak bezalako farmakoen eraginkortasuna aztertu da PG animalia-ereduetan, emaitza itxaropentsuak lortuz. Hala, nanoingeniaritzako partikulak oso tresna erabilgarria dirudite HHE gurutzatuz farmakoak modu seguru, eraginkor eta iraunkorrean emateko, eta beraz, PG bezalako nahasmendu neurologikoak tratatzeko etorkizun handiko estrategian bilaka daitezke.

show abstract

“…Similarly, Lopalco et al (2018) [ 142 ] functionalized DA-loaded liposomes with transferrin, a hydrophilic carrier that regulates the extracellular iron level in human fluid and whose receptor has been targeted for improving the BBB transport of drugs [ 143 ]. Other surface functionalization approaches have included the use of the amyloid precursor protein [ 144 ] and virus glycoproteins [ 145 ], among others [ 146 ].…”

Section: Controlled Drug Delivery On Parkinson’s Diseasementioning

confidence: 99%

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Padilla-Godínez

Ruiz-Ortega

Guerra-Crespo

2022

Cells

View full text Add to dashboard Cite

The complexity and overall burden of Parkinson’s disease (PD) require new pharmacological approaches to counteract the symptomatology while reducing the progressive neurodegeneration of affected dopaminergic neurons. Since the pathophysiological signature of PD is characterized by the loss of physiological levels of dopamine (DA) and the misfolding and aggregation of the alpha-synuclein (α-syn) protein, new proposals seek to restore the lost DA and inhibit the progressive damage derived from pathological α-syn and its impact in terms of oxidative stress. In this line, nanomedicine (the medical application of nanotechnology) has achieved significant advances in the development of nanocarriers capable of transporting and delivering basal state DA in a controlled manner in the tissues of interest, as well as highly selective catalytic nanostructures with enzyme-like properties for the elimination of reactive oxygen species (responsible for oxidative stress) and the proteolysis of misfolded proteins. Although some of these proposals remain in their early stages, the deepening of our knowledge concerning the pathological processes of PD and the advances in nanomedicine could endow for the development of potential treatments for this still incurable condition. Therefore, in this paper, we offer: (i) a brief summary of the most recent findings concerning the physiology of motor regulation and (ii) the molecular neuropathological processes associated with PD, together with (iii) a recapitulation of the current progress in controlled DA release by nanocarriers and (iv) the design of nanozymes, catalytic nanostructures with oxidoreductase-, chaperon, and protease-like properties. Finally, we conclude by describing the prospects and knowledge gaps to overcome and consider as research into nanotherapies for PD continues, especially when clinical translations take place.

show abstract

Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies

Cited by 27 publications

References 287 publications

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

Estrategia terapeutiko berritzaileak Parkinson gaixotasunean: nanopartikulak

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Contact Info

Product

Resources

About